Although PD-L1 expression in numerous types of tumor has increased the chance of clinical outcomes in some cancers with anti-PD-1–directed therapy, the lack of a clear definition of positive tumor PD-L1 staining through IHC is problematic. This evidence concerns the gene CD274 and neoplasm.